-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com
Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research report issued on Sunday. The firm set a "buy" rating on the stock.
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research note on Tuesday, July 5th.
Get Trinity Biotech alerts:Trinity Biotech Stock Down 3.3 %
NASDAQ TRIB opened at $1.17 on Friday. Trinity Biotech has a 12-month low of $0.86 and a 12-month high of $2.50. The company has a market capitalization of $31.49 million, a PE ratio of -2.29 and a beta of 1.34. The firm's 50 day moving average is $1.32 and its 200-day moving average is $1.23.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last posted its quarterly earnings data on Thursday, June 30th. The company reported ($0.08) earnings per share (EPS) for the quarter. Trinity Biotech had a negative net margin of 15.10% and a negative return on equity of 347.92%. The business had revenue of $18.78 million during the quarter.Hedge Funds Weigh In On Trinity Biotech
Hedge funds and other institutional investors have recently made changes to their positions in the company. Hunter Associates Investment Management LLC boosted its position in Trinity Biotech by 5.5% during the first quarter. Hunter Associates Investment Management LLC now owns 2,412,116 shares of the company's stock worth $2,557,000 after purchasing an additional 125,966 shares during the period. Renaissance Technologies LLC boosted its position in Trinity Biotech by 2.4% during the second quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company's stock worth $1,842,000 after purchasing an additional 34,900 shares during the period. Highbridge Capital Management LLC bought a new position in Trinity Biotech during the first quarter worth $1,221,000. Whitefort Capital Management LP boosted its position in Trinity Biotech by 1,067.8% during the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company's stock worth $434,000 after purchasing an additional 374,449 shares during the period. Finally, Envestnet Asset Management Inc. bought a new position in Trinity Biotech during the fourth quarter worth $159,000. 27.11% of the stock is owned by institutional investors.
About Trinity Biotech
(Get Rating)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a research report issued on Sunday. The firm set a "buy" rating on the stock.
斯托克新闻网的投资分析师在周日发布的一份研究报告中假设了利邦生物科技(纳斯达克:Trib-Get Rating)的股票。该公司对该股设定了“买入”评级。
Separately, TheStreet cut shares of Trinity Biotech from a "c-" rating to a "d" rating in a research note on Tuesday, July 5th.
另外,华尔街在7月5日星期二的一份研究报告中将利邦生物科技的股票评级从“c-”下调至“d”。
Trinity Biotech Stock Down 3.3 %
利邦生物科技股价下跌3.3%
NASDAQ TRIB opened at $1.17 on Friday. Trinity Biotech has a 12-month low of $0.86 and a 12-month high of $2.50. The company has a market capitalization of $31.49 million, a PE ratio of -2.29 and a beta of 1.34. The firm's 50 day moving average is $1.32 and its 200-day moving average is $1.23.
纳斯达克Trib上周五开盘报1.17美元。利邦生物科技的12个月低点为0.86美元,12个月高位为2.50美元。该公司市值为3,149万美元,市盈率为-2.29,贝塔系数为1.34。该公司的50日移动均线切入位在1.32美元,200日移动均线切入位在1.23美元。
Hedge Funds Weigh In On Trinity Biotech
对冲基金入股利邦生物科技
Hedge funds and other institutional investors have recently made changes to their positions in the company. Hunter Associates Investment Management LLC boosted its position in Trinity Biotech by 5.5% during the first quarter. Hunter Associates Investment Management LLC now owns 2,412,116 shares of the company's stock worth $2,557,000 after purchasing an additional 125,966 shares during the period. Renaissance Technologies LLC boosted its position in Trinity Biotech by 2.4% during the second quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company's stock worth $1,842,000 after purchasing an additional 34,900 shares during the period. Highbridge Capital Management LLC bought a new position in Trinity Biotech during the first quarter worth $1,221,000. Whitefort Capital Management LP boosted its position in Trinity Biotech by 1,067.8% during the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company's stock worth $434,000 after purchasing an additional 374,449 shares during the period. Finally, Envestnet Asset Management Inc. bought a new position in Trinity Biotech during the fourth quarter worth $159,000. 27.11% of the stock is owned by institutional investors.
对冲基金和其他机构投资者最近对他们在该公司的头寸进行了调整。Hunter Associates Investment Management LLC在第一季度将其在利邦生物科技的头寸提高了5.5%。Hunter Associates Investment Management LLC在此期间额外购买了125,966股,目前拥有2,412,116股该公司股票,价值2,557,000美元。复兴科技有限责任公司在第二季度将其在利邦生物科技的头寸增加了2.4%。复兴科技有限责任公司现在拥有1,503,336股该公司的股票,价值1,842,000美元,在此期间又购买了34,900股。Highbridge Capital Management LLC在第一季度购买了利邦生物科技的一个新头寸,价值1221,000美元。怀特福德资本管理公司在第一季度将其在利邦生物科技的头寸增加了1067.8%。怀特福德资本管理有限公司在此期间额外购买了374,449股后,现在拥有409,517股该公司股票,价值434,000美元。最后,Envestnet Asset Management Inc.在第四季度购买了利邦生物科技的一个新头寸,价值15.9万美元。27.11%的股份由机构投资者持有。
About Trinity Biotech
利邦生物科技公司简介
(Get Rating)
(获取评级)
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
利邦生物技术公司为美洲、非洲、亚洲和欧洲的诊断市场的临床实验室和护理点(POC)细分市场收购、开发、制造和营销医疗诊断产品。该公司提供临床实验室产品,包括诊断测试和仪器,用于检测传染病,如莱姆病;由梅毒和疱疹组成的性传播疾病;SARS-CoV-2;以及爱泼斯坦巴尔病毒、麻疹、腮腺炎、弓形体病、巨细胞病毒、风疹、水痘和其他病毒病原体,以及用于监测和诊断糖尿病并识别有糖尿病风险的人的血红蛋白A1c体外诊断测试的产品。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免费获取StockNews.com关于利邦生物科技的研究报告(Trib)
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
获得《利邦生物科技日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对利邦生物科技和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧